Invitation to a conference call and webcast by Isofol in connection with the entered license agreement with Solasia
GOTHENBURG, Sweden, August 13, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today announced that it entered into a license agreement with Solasia Pharma K.K (“Solasia”) (TSE: 4597), to develop and commercialize Isofol’s proprietary late-stage drug candidate arfolitixorin in Japan. In connection with this, Isofol invites investors, analysts and media to a conference call and webcast on August 13, 2020 at 11:00 (CEST).The presentation will be held by CEO Ulf Jungnelius in English and will conclude with a Q&A session. Questions can be asked